FOLH1 and posterior cortical atrophy: First patient studies have demonstrated excellent PSMA targeting for [68Ga/177Lu]PSMA-I&T, permitting high-contrast PET imaging of metastatic PCa with [68Ga]PSMA-I&T and, based on suitable uptake and retention characteristics, efficient treatment with its therapeutic analog [177Lu]PSMA-I&T [5, 6].